Activity dependent neurotrophic factor III (ADNF III)

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S023500, C435S006120, C435S320100, C435S325000

Reexamination Certificate

active

10623272

ABSTRACT:
The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.

REFERENCES:
patent: 5767240 (1998-06-01), Brenneman et al.
patent: WO92/18140 (1992-10-01), None
patent: WO96/11948 (1996-04-01), None
patent: WO98/35042 (1998-08-01), None
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides,vol. 71, No. 2, Aug. 15, 1997.
Bassan, M. et al. “Complete Sequence of a Novel ProteinContaining a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry,vol. 72, pp. 1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998,Abstracts,vol. 23, Part. I, p. 1043 (1998).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation,vol. 97, pp. 229-2307(1996).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997,Abstracts,vol. 23, Part 2, p. 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent neutotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics,vol. 285, pp. 619-627 (1998).
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts,vol. 23, Part 2, p. 2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation,vol. 99, pp. 28377-2841 (1997).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience Letters,Supplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts,vol. 23, Part 2, p. 2249 (1997).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology,vol. 134, pp. 2125 (1994).
Gozes, I. et al. “Superractive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics,vol. 273, pp. 161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA,vol. 93, pp. 427-432 (1996).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience,vol. 7, pp. 235-244 (1996).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology,vol. 33, pp. 329-342 (1997).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures; Immunological and Biological Specificity.”Developmental Brain Research,vol. 99, pp. 167-175 (1997).
Gozes, I, et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, October 25-30, 1997.Abstracts,vol. 23, Part 2, p. 2250 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience Letters,Supplement 48 S1-S60, p. S21 (1997).
Hill, J.M. et al. “Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiseum to Activity-Dependent Neurotrophic Factor (ADNF).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997,Abstracts,vol. 23, Part 2, p. 2250 (1997).
Lilling, G. et al. “Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist.”Journal of Molecular Neuroscience,vol. 5, pp. 231-239 (1995).
McKune, S.K. et al. “Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts,vol. 23, Part 2, p. 2249 (1997).
Nelbock, P. et al. A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator.Science,vol. 248, pp. 1650-1653 (1990).
Pelsman, A. et al. “In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides.” Society for Neuroscience, 28THAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts,vol. 24, p. 1044 (1998).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Activity dependent neurotrophic factor III (ADNF III) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activity dependent neurotrophic factor III (ADNF III), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activity dependent neurotrophic factor III (ADNF III) will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3778547

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.